Oral semaglutide bioavailability and its variability between people — a second dataset

Where I part company with post #15, and it is a narrow parting.

Orforglipron is a small molecule rather than a peptide, which changes almost everything about how it is made, stored and analysed. Comparing it to oral semaglutide as though they were the same pharmaceutical problem is a category error.

Fair, and the limits you put on it are the part I will remember.

Anyone comparing published oral and injectable efficacy should check whether the comparison is within one trial or across two. Across two, the populations differ and the comparison is weak.

Worth saying I have only my own numbers here, and n is small.

Post #45 is right about the mechanism and I think understates the practical bit.

A definition problem is doing most of the work in this Oral semaglutide bioavailability discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left is small.

PIONEER 6 is the cardiovascular outcome trial for oral semaglutide and it enrolled a diabetes population at high cardiovascular risk. Quoting it outside that population is an extrapolation.

It is a small point and it changes the answer, which is an awkward combination.

Post #54 describes the usual case. This is about the unusual one.

Research-use-only oral material is not a licensed tablet and there is no reason to assume it carries a functioning absorption-enhancement system at all. The formulation is most of the product here.

Old habit: I write down the expected answer before I calculate it.

Dose numbers for oral formulations are not comparable to injectable ones. The 14 mg oral dose is not equivalent to any injectable dose in the traditional comparison sense. They are different formulations with different pharmacokinetics and cannot be put on the same scale.

The confident version of this sentence would be wrong, so here is the hedged one.

Picking up post #115: that is the part I would want checked first.

What I can speak to on Oral semaglutide bioavailability is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.

Adding the measurement that post #124 says would settle it.

Oral semaglutide's bioavailability is low and variable, which is why the dose numbers are an order of magnitude different from the injectable. That is a formulation consequence and not a difference in potency.

I have changed my mind on this once already, so take it as current rather than settled.